Literature DB >> 10850449

Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas.

T D Schell1, B B Knowles, S S Tevethia.   

Abstract

The role of CTL tolerance in tumor immunity to SV40 large T antigen (T ag)-induced tumors was studied using T ag transgenic mice of the line 501 (H2b). 501 mice express SV40 T ag under the influence of the alpha-amylase promoter, which leads to the development of osteogenic osteosarcomas late in life and eventual death between 12 and 17 months of age. We determined the ability of 501 mice to respond to the four H2b-restricted T ag CTL epitopes, which include epitope I (T ag 206-215), epitope II/III (T ag 223-231), the immunorecessive epitope V (T ag 489-497), restricted by H2-Db, and epitope IV (T ag 404-411), restricted by H2-Kb. We demonstrate that 501 mice are partially tolerant to the H2b-restricted T ag epitopes. Immunization of 4-month-old 501 mice with T ag-transformed syngeneic cell lines or a recombinant vaccinia virus expressing full-length T ag elicited CTL responses against the H2-Kb-restricted T ag epitope IV only. In contrast, immunization of 4-month-old 501 mice with recombinant vaccinia viruses expressing individual T ag epitopes as minigenes elicited CTLs against epitopes I, IV, and V, but not against epitope II/III. Complete tolerance to epitopes I, IV, and V developed in 501 mice, but the age when tolerance was detected varied for each epitope. Tolerance to epitope I occurred by 6 months of age and was accelerated in the absence of CD4+ T cells. Tolerance to the immunorecessive epitope V was observed in 12-month-old 501 mice but was independent of the presence of osteosarcomas. In contrast, CTLs specific for epitope IV were detected in mice from 3 to 14 months of age but not in mice that had developed osteosarcomas. Analysis of epitope IV-specific CD8+ cells derived from 3-month-old 501 mice with H2-Kb/epitope IV tetramers revealed decreased numbers of epitope IV-specific CD8+ cells in 501 mice relative to C57BL/6 mice, with a further decrease in older 501 mice. Tumor progression resulted in loss of H2-Kb/epitope IV tetramer staining CD8+ cells. Thus, progression to tolerance to individual T ag CTL epitopes in 501 mice is epitope dependent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850449

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Hierarchy, tolerance, and dominance in the antitumor T-cell response.

Authors:  N P Restifo
Journal:  J Immunother       Date:  2001 May-Jun       Impact factor: 4.456

2.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

3.  Expression and immune recognition of SV40 Tag in transgenic mice that develop metastatic osteosarcomas.

Authors:  I Marton; S E Johnson; I Damjanov; K S Currier; J P Sundberg; B B Knowles
Journal:  Transgenic Res       Date:  2000-04       Impact factor: 2.788

4.  Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.

Authors:  Diego M Avella; Guangfu Li; Todd D Schell; Dai Liu; Samuel Shao-Min Zhang; Xi Lou; Arthur Berg; Eric T Kimchi; Hephzibah Rani S Tagaram; Qing Yang; Serene Shereef; Luis S Garcia; Mark Kester; Harriet C Isom; C Bart Rountree; Kevin F Staveley-O'Carroll
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

Review 5.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

6.  In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.

Authors:  Todd D Schell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  CD8+ T-cell cross-competition is governed by peptide-MHC class I stability.

Authors:  Ian Galea; Jana Stasakova; Melanie S Dunscombe; Christian H Ottensmeier; Tim Elliott; Stephen M Thirdborough
Journal:  Eur J Immunol       Date:  2011-11-28       Impact factor: 5.532

8.  Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach.

Authors:  Colin Campbell; Ranran Zhang; Jeremy S Haley; Xin Liu; Thomas Loughran; Todd D Schell; Réka Albert; Juilee Thakar
Journal:  Front Physiol       Date:  2011-07-11       Impact factor: 4.566

9.  Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.

Authors:  Adam J Adler; Anthony T Vella
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.

Authors:  Gerald Willimsky; Melinda Czéh; Christoph Loddenkemper; Johanna Gellermann; Karin Schmidt; Peter Wust; Harald Stein; Thomas Blankenstein
Journal:  J Exp Med       Date:  2008-06-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.